Administration of different antigenic forms of altered peptide ligands derived from HIV-1 RTase influences their effects on T helper cell activation

Human Immunology

Volumn 64, Issue 1, 2003, Pages 1-8

  Moschella, Federica ^a,b,c   Ombra, Maria Neve ^a,b,c   Del Pozzo, Giovanna ^a,b,c   Guardiola, John ^a,b,c  

^a Columbia University ^*  (United States)

^b CNR   (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Altered peptide ligands; HIV 1 peptides; Recombinant proteins; TCR recognition

Indexed keywords

EPITOPE; LIGAND; PEPTIDE; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR;

AMINO ACID SUBSTITUTION; ARTICLE; CELL ACTIVATION; GENETIC VARIABILITY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MUTANT; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR AFFINITY; VIRAL GENETICS;

EID: 0037239977     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(02)00783-8     Document Type: Article

References (41)

1. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 383:787, 1996.
2. Watts C, Powis S: Pathways of antigen processing and presentation. Rev Immunogenet 1:60, 1999.
3. Sloan-Lancaster J, Allen PM: Significance of T-cell stimulation by altered peptide ligands in T cell biology. Curr Opin Immunol 7:103, 1995.
4. Kersh GJ, Allen PM: Structural basis for T cell recognition of altered peptide ligands: A single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med 184:1259, 1996.
5. Chen YZ, Matsushita S, Nishimura Y: Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: Characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation. J Immunol 157:3783, 1996.
6. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA: A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 12:251, 2000.
7. Thomson CT, Kalergis AM, Sacchettini JC, Nathenson SG: A structural difference limited to one residue of the antigenic peptide can profoundly alter the biological outcome of the TCR-peptide/MHC class I interaction. J Immunol 166:3994, 2001.
8. Tissot AC, Ciatto C, Mittl PR, Grutter MG, Pluckthun A: Viral escape at the molecular level explained by quantitative T-cell receptor/peptide/MHC interactions and the crystal structure of a peptide/MHC complex. J Mol Biol 302:873, 2000.
9. Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN: Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267:515, 1995.
10. + T cells with enhanced functional characteristics: Implication for more effective immunotherapy. Cancer Res 59:301, 1999.
11. Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM: Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol 150(Pt 1):3131, 1993.
12. Chau LA, Bluestone JA, Madrenas J: Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor. J Exp Med 187:1699, 1998.
13. De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta FC, Grey HM, Sette A: Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68:625, 1992.
14. Bachmann MF, Speiser DE, Zakarian A, Ohashi PS: Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism. Eur J Immunol 28:3110, 1998.
15. Kersh GJ, Allen PM: Essential flexibility in the T-cell recognition of antigen. Nature 380:495, 1996.
16. Kersh GJ, Miley MJ, Nelson CA, Grakoui A, Horvath S, Donermeyer DL, Kappler J, Allen PM, Fremont DH: Structural and functional consequences of altering a peptide MHC anchor residue. J Immunol 166:3345, 2001.
17. Roberts JD, Bebenek K, Kunkel TA: The accuracy of reverse transcriptase from HIV-1. Science 242:1171, 1988.
18. Harcourt GC, Garrard S, Davenport MP, Edwards A, Phillips RE: HIV-1 variation diminishes CD4 T lymphocyte recognition. J Exp Med 188:1785, 1998.
19. Klenerman P, Rowland-Jones S, McAdam S, Edwards J, Daenke S, Lalloo D, Kopge B, Rosenberg W, Boyd D, Edwards A, Giangrande P, Phillips RE, McMichael AJ: Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369:403, 1994.
20. Davenport MP: Antagonists or altruists: do viral mutants modulate T-cell responses? Immunol Today 16:432, 1995.
21. Price DA, Meier UC, Klenerman P, Purbhoo MA, Phillips RE, Sewell AK: The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. J Mol Med 76:699, 1998.
22. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ongulesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR, McMichael AJ: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453, 1991.
23. Klenerman P, Meier UC, Phillips RE, McMichael AJ: The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur J Immunol 25:1927, 1995.
24. Brown AJ, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, Daar ES, D'Aquila RT, Keiset PH, Connick E, Hellmann NS, Petropoulos CJ, Richman DD, Little SJ: Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 74:10269, 2000.
25. Erickson JW, Gulnik SV, Markowitz M: Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13(Suppl A):S189, 1999.
26. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E: Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38:3919, 2000.
27. Myers GKB, Wein-Hobson S, Smith RF, Pavlakis GN: Human retroviruses and AIDS. Los Alamos National Laboratory. Los Alamos, NM, 1993.
28. Bouhdoud L, Villain P, Merzouki A, Arella M, Couture C: T-cell receptor-mediated anergy of a human immunodeficiency virus (HIV) gp120-specific CD4(+) cytotoxic T-cell clone, induced by a natural HIV type 1 variant peptide. J Virol 74:2121, 2000.
29. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ: Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci U S A 96:15050, 1999.
30. Nygard NR, Giacoletto KS, Bono C, Gorka J, Kompelli S, Schwartz BD: Peptide binding to surface class II molecules is the major pathway of formation of immunogenic class II-peptide complexes for viable antigen presenting cells. J Immunol 152:1082, 1994.
31. Davidson HW, Reid PA, Lanzavecchia A, Watts C: Processed antigen binds to newly synthesized MHC class II molecules in antigen-specific B lymphocytes. Cell 67:105, 1991.
32. Viner NJ, Nelson CA, Deck B, Unanue ER: Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J Immunol 156: 2365, 1996.
33. Finnegan A, Regan J, Seamon KB, Lindholm C: Identification of single amino acid substitutions in the staphylococcal nuclease protein that enhance and diminish T cell clone recognition of naturally processed peptides. Int Immunol 4:1399, 1992.
34. Manca F, De Berardinis P, Fenoglio D, Ombra MN, Li Pira G, Saverino D, Autiero M, Lozzi L, Bracci L, Guardiola J: Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection. Eur J Immunol 26:2461, 1996.
35. Prisco A, Bonomi G, Moschella F, Ombra MN, De Berardinis P, Guardiola J: In vitro immunization with a recombinant antigen carrying the HIV-1 RT248-262 determinant inserted at different locations results in altered TCRVB region usage. Hum Immunol 60:755, 1999.
36. Bonomi G, Moschella F, Ombra MN, Del Pozzo G, Granier C, De Berardinis P, Guardiola J: Modulation of TCR recognition of MHC class II/peptide by processed remote N- and C-terminal epitope extensions. Hum Immunol 61:753, 2000.
37. Sloan-Lancaster J, Allen PM: Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 14:1, 1996.
38. Moudgil KD, Grewal IS, Jensen PE, Sercarz EE: Unresponsiveness to a self-peptide of mouse lysozyme owing to hindrance of T cell receptor-major histocompatibility complex/peptide interaction caused by flanking epitopic residues. J Exp Med 183:535, 1996.
39. Moudgil KD, Sercarz EE, Grewal IS: Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol Today 19:217, 1998.
40. Fenoglio D, Li Pira G, De Berardinis P, Saverino D, Terranova MP, Ombra MN, Bracci L, Lozzi L, Viotti C, Guardiola J, Manca F: Antagonistic activity of HIV-1 T helper peptides flanked by an unrelated carrier protein. Eur J Immunol 29:1448, 1999.
41. Rotzschke O, Falk K, Mack J, Lau JM, Jung G, Strominger JL: Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes. Proc Natl Acad Sci U S A 96:7445, 1999.